Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo

See also
Status	Clinical Trial	Phase
Completed	`NCT05038982` - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin	Phase 2
Completed	`NCT00869089` - Safety and Efficacy of CC-10004 for Prurigo Nodularis	Phase 2
Completed	`NCT04501666` - An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis	Phase 3
Completed	`NCT03181503` - Safety and Efficacy of Nemolizumab in PN	Phase 2
Completed	`NCT03630198` - Pain Outcomes Following Intralesional Corticosteroid Injections	Phase 4
Completed	`NCT04944862` - A Study of CDX-0159 in Patients With Prurigo Nodularis	Phase 1
Completed	`NCT05061693` - A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis	Phase 2
Completed	`NCT03546816` - Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis	Phase 3
Recruiting	`NCT06293053` - A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis	Phase 3
Not yet recruiting	`NCT06201715` - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis	N/A
Completed	`NCT02174419` - Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis	Phase 2/Phase 3
Terminated	`NCT03540160` - Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)	Phase 3
Recruiting	`NCT06427122` - Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life	N/A
Completed	`NCT03816891` - Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis	Phase 2
Recruiting	`NCT05764161` - A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)	Phase 3
Completed	`NCT02196324` - A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Phase 2
Not yet recruiting	`NCT06424470` - Study on the Treatment of Prurigo Nodularis With Stapokibart Injection	Phase 3
Recruiting	`NCT03576287` - Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis	Phase 1/Phase 2
Completed	`NCT05052983` - A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis	Phase 3
Active, not recruiting	`NCT04204616` - A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)	Phase 3

NCT number	NCT02174432
Study type	Interventional
Source	Trevi Therapeutics
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	August 15, 2015
Completion date	September 3, 2017

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms